Maravai LifeSciences Holdings Inc

MRVI remains in a clear Stage 2 advance with strong higher highs and higher lows, supported by steeply rising short-term EMAs and constructive volume. However, price is extended well above the 9/21/50 EMA zone with extreme overbought conditions, reducing immediate entry viability. Medium-term bias stays bullish underpinned by the active Parabola acceleration and intact trend structure, but heightened reversal risk demands patience. Execution should be deferred into pullbacks to the rising EMA support area. Primary risks include abrupt reversals from acceleration extremes, failure of EMAs to hold support, and potential Stage 2→3 transition if exhaustion intensifies.

• ↑Q1 2026 revenue $65.8M (+41% YoY), TriLink up 65%.
• ↑Free cash flow $4.2M positive, first since Q3 2024.
• ↓Negative earnings yield and weak profitability factors persist.